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1. Introduction
Amyloidosis is a disorder of protein conformation and metabolism that results in the depo‐
sition of insoluble amyloid fibrils in tissues, which causes organ dysfunction; systemic amy‐
loidosis is characterized by failure of multiple organs and the presence of amyloid precursor
protein in the serum [1-3]. Reactive amyloid A (AA) amyloidosis is one of the most severe
complications of several chronic disorders, particularly rheumatoid arthritis (RA) [4], and
indeed, most patients with reactive AA amyloidosis have an underlying rheumatic disease.
An extra-articular complication of RA, AA amyloidosis is a serious, potentially life-threaten‐
ing disorder caused by deposition in organs of AA amyloid fibrils, which derive from the
circulatory acute-phase reactant, serum amyloid A protein (SAA) [5]. AA amyloidosis sec‐
ondary to RA is thus one of the intractable conditions found in patients with collagen vascu‐
lar diseases and is an uncommon yet important complication of RA [6]. However, the actual
pathological mechanisms that are responsible for the relationship between SAA and AA
amyloidosis have not been fully elucidated.
With new biological therapies, both treatment and understanding of the roles of cytokines
and inflammatory cellular events in RA have seen considerable progress. Biologics are rec‐
ommended for patients with RA who have a suboptimal response or an intolerance to tradi‐
tional disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX).
Early diagnosis and rapidly subsequent treatment are essential because patients with ad‐
vanced disease can’t usually undergo intensive therapy. Specific treatment of AA amyloido‐
sis caused by RA aims to stop SAA production. Cytotoxics such as chlorambucil and
cyclophosphamide (CYC) and biologics such as anti-tumor necrosis factor (TNF)α inhibitors
and anti-interleukin (IL)-6 receptor antibody are reportedly useful for both RA and AA
amyloidosis [7, 8]. By the way, the genetic predisposition allele SAA1.3, one of SAA1 gene
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polymorphism, can serve not only as a risk factor for the association of AA amyloidosis, but
also as a poor prognostic factor in Japanese RA patients [9]. Both the association of AA amy‐
loidosis arising early in the RA disease course and symptomatic variety and severity were
found in amyloidotic patients carrying SAA1.3 allele. Etanercept (ETN) for patients with AA
amyloidosis secondary to RA, who carry SAA1.3 allele, showed the amelioration of rheuma‐
toid inflammation, including marked reduction of SAA, improvement of proteinuria and
creatinine clearance [10], that would demonstrate efficacy and safety even in patients under‐
gone on hemodialysis [11]. These lead us to the notion of clinical significance of SAA1.3 al‐
lele in the clinical strategy of Japanese RA patients.
This article will discuss on therapeutic strategies from the point of biologics view on RA
treatment in relation to AA amyloidosis secondary to RA based on our reports and literature
reviews.
2. Significance of SAA1.3 allele genotype in Japanese RA patients with
AA amyloidosis
It was reported that the frequency of SAA1.3 allele was markedly increased in AA amyloi‐
dosis in Japanese RA patients (Fig. 1), suggesting that this allele was a risk factor for AA
amyloidosis secondary to RA [12]. That is, SAA1.3 allele has been reported to be associated
with increased risk of AA amyloidosis and SAA1.1 with decreased risk [13], while SAA1.1
was revealed to be a risk factor for developing AA amyloidosis in the Caucasian population
[14]. We calculated the hazard ratio in the presence or absence of SAA1.3/1.3 homozygosity
as a survival parameter after the onset of RA. By means of Cox proportional hazard survival
analysis, carrying with SAA1.3/1.3 homozygosity was statistically significant for survival
(P=0.015) with hazard ratio of 2.101 (95% CI: 1.157 - 3.812). Also, the Kaplan-Meier curve
showed a significant difference during observation from diagnosis of RA (Fig. 2). The mean
survival period of the all patients with and without SAA 1.3/1.3 was 6.52±6.18 years and
13.8±8.47 years, with 43.8% and 71.6% surviving for 10 years, respectively. The SAA1.3 al‐
lele, particularly homozygosity for SAA1.3, was a univariate predictor of survival. The pre‐
senting factors which adversely influenced clinical outcome after diagnosis of AA
amyloidosis were age (P=0.001), raised serum creatinine (Crea) concentration (P=2.14 X 10-5),
lowered serum albumin (Alb) concentration (P=0.001), and presence of SAA1.3/1.3 (P=0.035).
While, after diagnosis of RA, age of RA onset (P=2.95 X 10-4) and presence of renal involve‐
ment (P=0.011) were extracted as survival parameter. The serum Crea value of >2.5mg/dl
upon diagnosis of AA amyloidosis was closely related with poorer survival, when com‐
pared with a serum Crea value of ≦2.5mg/dl by Kaplan-Meier technique (P=0.013 with log-
rank statistic) (Fig. 3). The presence of cardiac involvement was likely to be a risk factor to
survival (P=0.062). These results have revealed the significance of SAA1.3 allele genotype in
Japanese RA patients with AA amyloidosis when we follow-up such patients in daily prac‐
tice [15, 16]. However, we just need more studies about the large prospective trials to prove
the usefulness of SAA1.3 allele genotype.
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 Figure 1. SAA1.3 allele frequency and AA amyloidosis in Japanese RA patients. SAA1.3 allele is associated with in‐
creased risk of AA amyloidosis in Japanese RA patients. Figures are courtesy of Satoshi Baba, MD and modified from
Reference No. 12.
Figure 2. Kaplan-Meier survival curve in RA disease course for RA patients with (continuous line) and without (dotted
line) SAA1.3/1.3 (P=0.015, log-rank test) from Reference No. 9.
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Figure 3. Kaplan-Meier survival curve after diagnosis of AA amyloidosis for patients with serum creatinine >2.5mg /dl
(continuous line) and serum creatinine ≦2.5mg/dl (dotted line) (P=0.013, log-rank test) from Reference No. 9.
3. Fundamental thoughts for therapies
According to the information on the studies using radiolabelled human serum amyloid
component P (SAP) as a specific quantitative in vivo scintigraphic tracer for monitoring of
systemic AA amyloidosis [17], treatments those effectively suppress production of SAA halt
the progressive accumulation of AA amyloid deposits and, in many cases, they are associat‐
ed with AA amyloid regression, improved organ function and survival [18, 19]. AA amyloid
deposits are evidently turning over, their net size reflecting the balance of deposition and
regression [20]. Therefore, AA amyloid deposits may regress at a low rate over a period of
years and exist in a sate of dynamic turnover. The usual clinical impression of inexorable
progression of AA amyloidosis actually reflects the progressive and usually incurable na‐
ture of the underlying primary condition, which is complicated by AA amyloidosis. Howev‐
er, new and aggressive approaches to therapy, such as cytotoxic anti-inflammatory drugs
and biologic agents in chronic rheumatic inflammation, will lead to impressive AA amyloid
regression and prolonged survival. Unfortunately these treatments do not always work and
there are many difficult cases in those approaches are neither possible now nor likely to be‐
come feasible in future. In view of clinical significance of AA amyloidosis, there is an urgent
need to facilitate studies into this complication. Early diagnosis and intervention are essen‐
tial for RA, however, few specific features are useful for diagnosis of RA and its diagnosis is
often difficult in daily RA practice. Reduction of SAA load is currently the most rational ap‐
proach thereby arresting further deposition [21]. It is not exactly known why some patients
develop a progressive AA amyloidosis while others do not, although latent deposits may be
present. While there is startling variation in the frequency of AA amyloidosis worldwide,
differences also exist for AA amyloidosis complicating RA [22]. The reasons, however, for
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the marked geographic differences are unclear. The difference in the frequency of AA amy‐
loidosis among different races, and the fact that AA amyloidosis is not consistently related
to the length and severity of chronic inflammation suggests that AA amyloidosis may be, at
least in part, influenced by genetic factors [23-25].
4. Treatments of AA amyloidosis secondary to RA
The principal aim in treating RA patients with AA amyloidosis is to switch off SAA produc‐
tion by controlling the RA inflammatory process. Anti-inflammatory treatment must be em‐
pirical but, as in all patients with AA amyloidosis, should be guided by frequent assessment
of SAA concentrations in view of reported correlations between survival and this measure.
Treatment of AA amyloidosis secondary to RA may involve the following strategies as out‐
lined in Table 1 [26].
Prevention (1)Be careful not to raise AA amyloidosis
(2)Keep the serum levels of SAA3)less than 10 μg/ml
(3)Control tightly rheumatoid inflammatory responses
(4)Follow-up RA patients carrying SAA1.3 allele carefully
Diagnosis (1)Do not underestimate proteinuria
(2)Evaluate renal function by the levels of eGFR4), cystatin C, and Ccr5)
(3)Watch GI6) tract symptoms
(4)Detect AA amyloid fibrils with organ biopsy like GI tracts, labia, and abdominal
subcutaneous fat
(5)Require renal biopsy in cases with proteinuria or renal dysfunction in RA patients
Therapy: (1)Control acute-phase responses to suppress the synthesis of SAA
(2)Control RA disease activity tightly
(i) Do not lose window of opportunity
(ii) Control RA disease tightly according to T2T7) recommendations even in patients
undergoing HD8)
(iii) Choose MTX9) plus biologics in cases uncontrollable from early phase
(iv) Challenge new biologics and signal transduction inhibitors
(3)Steroid, codeine phosphate, lactate bacteriae, and especially octreotide for refractory
diarrhea
(4)Stand on the notion of deposited AA amyloid fibrils existing in a state of dynamic turnover
1)AA:amyloid A, 2)RA:rheumatoid arthritis, 3)SAA:serum amyloid A protein, 4)eGFR: estimated glomerular filtration rate,
5)Ccr:creatinine clearance, 6)GI:gastrointestine, 7) T2T: treat RA to target, 8) HD:hemodialysis,9)MTX:methotrexate
Table 1. Clinical strategies in the management of AA1) amyloidosis secondary to RA2)
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4.1. Suppression of SAA production
For AA amyloidosis in patients with RA, treatment has centered on using cytotoxic agents
and is shifting to biologics recently. Although case reports and studies of small series of pa‐
tients showed that these agents can reverse nephrotic syndrome and even lead to complete
resolution of proteinuria, anticytokine agents have recently been proposed as therapeutic
options. Traditional management of AA amyloidosis has been to target RA disease to proc‐
ess behind the inflammation. Although there is no evidence that DMARDs have a specific
effect on amyloidogenesis and AA amyloidosis in RA [27, 28], there have been encouraging
reports evaluating alkylating agents as beneficial in clinical trials in RA patients with AA
amyloidosis [29-33]. Treatments in AA amyloidosis secondary to RA including immunosup‐
pressants, biologics, and other supportive therapies will be discussed as follows.
4.1.1. Immunosuppressants
It is suggested that the use of immunosuppressive agents can improve prognosis [34], and
CYC was superior to MTX in the management of RA patients with AA amyloidosis [9]. As
regards MTX and CYC treatments, we observed differences of both serum C-reactive pro‐
tein (CRP) and Crea concentrations. That is, we subtracted the CRP- and/or Crea-value at
initiation from the CRP- and/or Crea-value at endpoint of corresponding to each treatment.
The each deducted value was dotted in Fig. 4. It was clear that more CYC treatments resided
within minus area than MTX treatments. CRP improved 1.23±1.67 (mg/dl) in CYC treat‐
ments with statistical significance (P<0.001). We reported the possibility that CYC would be
more effective predominantly in patients with SAA1.3/1.3 homozygosity than heterozygosi‐
ty, suggesting of CYC treatment-susceptible factor as SAA1.3/1.3 homozygosity [35]. Con‐
cerning immunosuppressants, whether specific therapies were warranted and were superior
to previously reported regimens should be elucidated. The strategy of these treatments fo‐
cuses on tight control of underlying RA disease activity [28]. Requirements include diagno‐
sis of RA as early as possible and treatment with DMARDs, including MTX as the anchor
drug. Achieving low disease activity via DMARDs in the early disease course has a strong
positive outcome on disease progression. However, although MTX is the most common and
effective drug for RA, management of patients with AA amyloidosis secondary to RA and
renal involvement is too complex to limit the discussion on MTX.
For signal transduction, IL-6 binds to membrane-bound IL-6 receptor gp80 [36], and then the
IL-6-gp80 dimer interacts with gp130. Formation of gp130-containing complexes leads to ac‐
tivation of Janus kinases (JAKs), which stimulates signal transducers and activators of tran‐
scription (STATs) [37]. Certain evidence suggests that STAT3 is the key transcription factor
responsible for IL-6 activation of SAA gene transcription [38]. Therefore, the function of JAK
inhibition in the IL-6 signaling pathway will be one target of RA treatments. Suppressing
IL-6-mediated proinflammatory signaling pathways via JAK inhibitors may be a novel anti-
inflammatory therapeutic strategy for RA and AA amyloidosis. Another agent, tacrolimus,
may inhibit T-cell function in pathogenesis of AA amyloidosis. The function of JAK inhibi‐
tion in the IL-6 signaling pathway will be one target of RA treatments [39, 40].
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Figure 4. Differences between CYC and MTX treatments for RA patients with AA amyloidosis. The detected value
(placed in figures) was calculated by subtracting the starting value of CRP and/or serum creatinine from the endpoint
value in each treatment from Reference No. 9.
4.1.2. Biologics
In RA treatment, tight control of RA is emphasized to obtain clinical remission or lower dis‐
ease activity; this control is possible through periodic evaluations of RA disease activity and
aggressive pursuit of other more effective treatments [41-43]. Anti-proinflammatory cyto‐
kine therapy is expected to show efficacy against both systemic and local inflammation
mediated by macrophage differentiation or activation in glomeruli, such as in renal AA
amyloidosis secondary to RA [44].
Infliximab (IFX) and ETN, both TNFα antagonists, can reduce serum SAA levels in RA pa‐
tients with AA amyloidosis, which improves rheumatoid inflammation, reduces swollen
and tender joint counts, lowers or normalizes proteinuria, and ameliorates renal function
[45-48]. Also, these agents showed amelioration in renal function for AA amyloidosis secon‐
dary to RA (Table 2) [10]. Despite the small number of series of patients with AA amyloido‐
sis secondary to RA who had ETN treatment, this drug did benefit both RA inflammation
and AA amyloidosis, as measured via the surrogate markers, disease activity score (DAS)28-
erythrocyte sedimentation rate (ESR), CRP, SAA, and proteinuria, in SAA1.3 allele-carrying
RA patients (Fig. 5, Table 3). Further, Crea levels significantly improved in patients with
mild RA disease and renal dysfunction (Table 4). This result suggests that the earlier the in‐
tervention with biologics, the better the outcome for patients. ETN alone may therefore be
efficacious, without MTX [49-53].
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Figure 5. Chronological changes among surrogate markers following etanercept treatment. Ccr: creatinine clearance,
CRP: C-reactive protein, DAS: disease activity score, n: number of patients treated with etanercept in the designated
observation periods. CRP decreased dramatically by 20 weeks (P=0.018) and DAS28-ESR improved to low values signif‐
icantly following the treatment of etanercept. Although serum and calculated Ccr are coincided to be renal function
markers, only serum albumin showed stastical significance between 0 and 96 weeks ( P=0.003), whereas the calculat‐
ed creatinine clearance fell gradually 0 and 96 weeks (P=0.776).
Case/Age/Sex Duration (years) Biologics Proteinuria (g/day) Serum Crea
(mM/L)
Observation
Periods
(months)RA AA
amyloidosis
Initial Last Initial Last
1/70/F 18 1 IFX 2 6 93 130 3
2/59/F 13 4 ETN 1.2 0.2 398 425 12
3/59/F 13 4 ETN 1.2 0.72 229 246 7
4/37/M 22 2 IFX 3 0.9 134 145 17
Quoted and modified from Reference No. 47. Data are represented as renal functions between the initial- and last-vist
following biologics treatment. RA: rheumatoid arthritis, AA: amyloid A, Crea: levels of creatinine, IFX: infliximab, ETN:
etanercept.
Table 2. Effect of TNF alpha blockers on renal AA amyloidosis secondary to RA.
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Parameter Initial-visit Last-visit P-value
RA inflammation
DAS28-ESR 5.99±0.69 2.99±0.15 <0.01
CRP(mg/dl) 4.68±0.87 0.48±0.29 <0.01
AA amyloidosis
SAA(μg/ml) 250±129 26±15 <0.01
Proteinuria(g/day) 2.24±0.81 0.57±0.41 <0.01
Serum creatinine(mg/dl) 2.54±1.38 2.50±2.21 0.896
The values of DAS28=ESR, CRP, SAA, and proteinuria between the initial visit (before eta‐
nercept) and the last treatment (the index time) with etanercept. All improved with statisti‐
cal significance. In contrast, the serum creatinine did not change statistically. RA:
rheumatoid arthritis, DAS: disease activity score, ESR: erythrocyte sedimentation rate, CRP:
C-reactive protein, AA: amyloid A, SAA: serum amyloid A protein, *serum levels. Quoted
and modified from Reference No. 10.
Table 3. Surrogate markers between initial- and last-visit following treatment with etanercept
μ
Less than 2.0(mg/dl) More than 2.0(mg/dl) 
(n=6) (n=8) 
Initial-visit Last-visit Initial-visit Last-visit 
(mg/dl) (mg/dl) (mg/dl) (mg/dl) 
1.37±0.49 1.07±0.59 3.43±1.14 3.56±2.39 
* ** 
α
*P=0.021,**not significant
Although Table 3 shows that the change in serum creatinine value was not statistically significant, when using a cutoff val‐
ue as less than 2.0 mg/dl at the initial-visit, it was demonstrated that the creatinine value improved significantly at the last-
visit. Quoted and modified from Reference No. 10.
Table 4. Changes in the values of serum creatinine statifying by 2.0(mg/dl) at the commencement of etanercept
Tocilizumab (TCZ), an IL-6 receptor antagonist, can demonstrate excellent suppression of SAA
levels and may have potential as the first candidate of the therapeutic agent for AA amyloidosis
[7]. Circulating SAA normally reflects changes in CRP, and levels of both acute-phase reactants
usually increase simultaneously, but some differences can occur. SAA and CRP seem to be part‐
ly influenced by different cytokines. IL-6-blocking therapy has shown promise in normalizing
serum SAA levels in RA patients. Moreover, blocking IL-6 alone, but not IL-1 or TNFα, complete‐
ly prevented SAA mRNA expression in human hepatocytes during triple cytokine stimulation
[54, 55]. Some reports with promising effect on AA amyloidosis secondary to RA may suggest a
possibility of usefulness of this agent [56, 57]. Our case with end-stage renal disease due to AA
amyloidosis secondary to RA showed validity of TCZ usage which is reaching to sustain normal
SAA levels with successive treatment for 4 years (Fig. 6). In this case due to loss of joint function in
advanced RA stage, in spite of lower and limited quality of life, both CRP and SAA are keeping
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within normal limits, those may lead to decreasing proteinuria. It is needed to clarify the dissoci‐
ation between inflammatory rheumatoid activity and destructed articular function under cur‐
rent RA therapeutic strategies using biologics like “disconnect” phenomenon [58].
TCZ 280mg/month ETN 25mg/week 
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Figure 6. Effect of tocilizumab on AA amyloidosis secondary to RA. DAS28-ESR showed gradually regressed with the
association of CRP, however, levels of serum creatinine increased leading to end-stage renal disease. TCZ had an effect
on both proteinuria and rheumatoid inflammation, nevertheless, this case showed late dissociation between rheuma‐
toid inflammation and joint functional activity. TCZ: tocilizumab, ETN: etanercept, PSL: prednisolone, Crea: serum crea‐
tinine, CRP: C-reactive protein.
T lymphocyte costimulation is a key point in the regulation of immune tolerance, immune
response, and autoimmunity. T lymphocyte activation does not take place upon the simple
engagement of T cell receptor; a second signal is needed to fully stimulate T lymphocytes.
There are a variety of molecules that can act as costimulators, and among these cluster of
differentiation (CD)28/CD80 signaling plays a crucial role in modulating T lymphocyte re‐
sponse. Cytotoxic T lymphocyte antigen-4 (CTLA4) is a physiologic antagonist of CD28, and
abatacept (ABT), a synthetic analogue of CTLA4, has recently been approved to treat RA. A
70-year-old Japanese woman had been suffering from RA for 28 years with Steinbrocker’s
Stage IV and functional Class 2. She was biopsy-confirmed as AA amyloidosis carried with
SAA1.3/1.5 allele genotype. ABT was initiated from January 2011 and her clinical course was
shown in Fig. 7. The histopathological findings from upper gastrointestinal (GI) biopsy be‐
tween before and after 1 year from the commencement of ABT revealed a disappearance of
AA amyloid fibril deposition (Fig. 8-A, -B). The changes in markers on cytokines and lym‐
phocyte expression might suggest an effect of ABT from the points of immunological aspect
in the case (Table 5). These results would show effectiveness of this agent on both RA and
AA amyloidosis, with being required further elucidations. In experimental mouse models of
AA amyloidosis, blocking T lymphocytes function by the calcinulin inhibitor showed that
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tacrolims inhibited AA amyloid fibril deposits in a dose-dependent manner without influ‐
encing SAA concentrations. Also, the locality of CD4+ T lymphocytes in the spleen was par‐
tially identical to AA amyloid fibril deposits histologically, suggesting the role of T
lymphocytes in the pathogenesis of AA amyloidosis [39].
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Figure 7. Effect of abatacept on AA amyloidosis secondary to RA. Inflammatory markers, CRP and SAA, decreased
gradually, and renal dysfunction ameliorated with the treatment of abatacept. ABT: abatacept, eGFR: estimated glo‐
merular filtration rate, SAA: serum amyloid A protein, CRP: C-reactive protein, mHAQ: modified health assessment
questionnaire, DAS: disease activity score, ESR: erythrocyte sedimentation rate.
Figure 8. Histological changes before (A) the treatment with abatacept and after (B) one year in the disease course.
Amorphous deposits were detected in the specimen from upper gastrointestinal biopsy with Congo Red staining (A).
Those disappeared with abatacept treatment after one year (B).
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Parameter Baseline Clinical course (month)   
 (n=14) 0 3 6 9 12
IL-6 (pg/ml) 11.2±12.9 107 40.4 24.8 7.6 1.7
TNFα (pg/ml) 1.04±0.36 2.2 1.4 1.3 1.1 1.1
IL-2 (U/ml) <0.8 <0.8 <0.8 <0.8 <0.8 <0.8
CD4+/CD8+ 1.30±0.58 2.04 1.63 1.54 1.72 1.77
CD4+CD25++FoxP3+ reg T cells
gated on
Lymphocytes (%) 1.60±0.85 4.8 2.6 2.1 2.4 2.4
CD4+ T lymphocytes (%) 4.79±1.60 9 5.4 4.8 5.2 5.1
Baseline values were determined and expressed by mean ± S.D. of 14 RA patients, matched by disease duration and
disease severity to this case. IL-6: interleukin-6, TNFa: tumor necrosis factor alpha, IL-2: interleukin -2, reg T: regulatory
T lymphocyte.
Table 5. Changes in cytokines and regulatory T lymphocyte expression after abatacept treatment
Rituximab (RTX), an anti-CD20 monoclonal antibody, was efficacious for patients with se‐
vere active RA who have exhibited an inadequate response to one or more TNFα inhibitors
[59]. Also, this agent was administered alone in two RA patients and in combination with
MTX in other two RA cases with histologic confirmation of AA amyloidosis. The four pa‐
tients showed a significant clinical improvement of the articular symptoms and marked re‐
duction of the acute phase-reactants. Renal function remained stable in all patients and
proteinuria improved in two, worsened in one, and remained stable in the fourth with few
adverse effects [60].
Clinical trials are warranted to assess the long-term safety and efficacy of biological treat‐
ments and their impacts on the survival of RA patients with AA amyloidosis.
4.1.3. Corticosteroids
The effect of corticosteroid treatment on AA amyloidosis is still controversial. Corticoste‐
roids are capable of reducing the magnitude of the acute phase reaction including the syn‐
thesis of CRP and SAA. In human hepatocyte cultures a stimulating effect of corticosteroids
was seen on SAA but not on CRP production [61, 62]. Although corticosteroid therapy sup‐
presses both CRP and SAA levels in longitudinal studies of patients with RA, the effect is
somewhat more pronounced for CRP than for SAA [63]. Monitoring of SAA instead of CRP
levels would be advisable particularly if corticosteroids are being used. It seems reasonable
to treat patients with AA amyloidosis secondary to RA using cytostatic drugs either alone or
in combination with prednisolone [64-66]. As the effect of cytostatics may take weeks or
months to appear, it is recommended to give steroids additionally in order to ensure an im‐
mediate reduction of the acute phase response and in particular the synthesis of SAA. Low-
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dose prednisolone inclusion in a MTX-based tight control strategy for early RA would be
effective, thus could be improved for AA amyloidosis secondary to RA [67].
4.2. Inhibition of AA amyloid fibril deposits
Eprodisate, a small sulfonated molecule with structural similarity to heparan sulfate, which
can cause regression of amyloidosis by destabilizing the glycoasaminoglycan backbone of
amyloid deposits, delayed progression of renal disease associated with AA amyloidosis. In a
trial for AA amyloidosis, eprodisate had a beneficial effect on the rate of deterioration of re‐
nal function but no effect on urinary protein excretion [68]. Because eprodisate did not affect
SAA levels and preserved kidney function but had no effect on proteinuria, the interesting
possibility that it is the precursors of mature amyloid fibrils are responsible for proteinuria
in amyloidosis would raise. In the light of higher effects of biologics on AA amyloidosis sec‐
ondary to RA, the usefulness of eprodisate seems to be inferior to that of biologic under the
biologics era.
4.3. Removal of deposited AA amyloid fibrils
The normal plasma protein SAP binds to all types of amyloid fibrils and contributes to amy‐
loidosis pathogenesis [69]. A pyrrolidine carboxylic acid derivative, which is a competitive
inhibitor of SAP binding to amyloid fibrils, can intervere in this process and affect SAP lev‐
els. This compound cross-linked and dimerized SAP molecules, which led to extremely rap‐
id clearance by the liver, and thus produced marked depletion of circulating human SAP.
Therefore, this drug action removed SAP from human amyloid deposits in tissues and may
have a favorable effect on amyloidosis [70].
Another compound, dimethyl sulfoxide (DMSO), is a hydrogen-bond disrupter, cell-differ‐
entiating agent, hydroxyl radical scavenger, cryoprotectant, and solubilizing agent that is
used as a compound for preparation of samples for electron microscopy, as an intracellular
low-density lipoprotein-derived cholesterol-mobilizing antidote to extravasation of vesicant
anticancer agents, and as a topical analgesic. A notable DMSO side effect is garlic-like breath
odor and taste in the mouth because of pulmonary excretion of a small amount of DMSO as
dimethyl sulfide [71]. Oral DMSO was effective against AA amyloidosis, especially GI in‐
volvement and early renal dysfunction [72], but using it would not likely be feasible in cur‐
rent clinical practice.
4.4. Treatment of organ failure
The predominant feature of AA amyloidosis is proteinuria with or without renal failure. If con‐
servative treatment of renal failure is not sufficient, renal replacement therapy including renal
transplantation, continuous ambulatory peritoneal dialysis, or hemodialysis (HD) should be
considered. Even in RA patients with AA amyloidosis who undergo HD, anti-TNFα blockers
can demonstrate efficacy [11, 73]. HD reportedly had no effect on plasma ETN concentration,
and ETN pharmacokinetics in patients undergoing HD for chronic renal failure were similar to
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those with normal renal function [74]. Administration of ETN to HD patients would therefore
appear reasonable. Renal replacement therapy is discussed in Table 6.
Renal transplantation
Immonen K, et al: J Rheumatol 2008; 35: 1334-8
30 cases in 332 RA patients with AA amyloidosis
Median survival: 2.11 years
Peritoneal dialysis/Hemodialysis (HD)
Bergesio F, et al: Nephrol Dial Transplant 2008; 23: 941-51
Prognosis: 17 months
Kuroda T, et al: Reference No. 73
96.9 person-year followup: 42 patients died
50% survival from the initiation of HD: 251 days
Ccr was superior to Crea, Advisable planned initiation of HD
Nakamura T, et al: Reference No. 11
51.8 months Dialysis with ETN 27.8 months Use
Amelioration of DAS28-ESR, CRP, mHAQ, and ESR
RA: rheumatoid arthritis, AA: amyloid A, HD: hemodialysis, Ccr: creatinine clearance, Crea: serum levels of creatinine,
ETN: etanercept, DAS: disease activity score, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, mHAQ:
modified health assessment questionnaire.
Table 6. Renal replacement therapy in AA amyloidosis secondary to RA
5. Comparison of effectiveness between biologic and alkylating agent
We previously showed that the genetic predisposition allele SAA1.3 was not only a univari‐
ate predictor of survival but also a risk factor for association of AA amyloidosis with RA in
Japanese patients [9], and in view of our earlier reports on the efficacy of ETN [10, 48] and
CYC [35, 64] given alone for AA amyloidosis secondary to RA, we compared the effective‐
ness of ETN and CYC, and we assessed biomarkers and analyzed the effect of SAA1.3 allele
on these treatments [75].
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5.1. Patients and methods
This retrospective cohort study compared effectiveness of CYC and ETN for RA patients
with AA amyloidosis who were homozygous for the SAA1.3 allele or other polymorphisms.
Sixty-two RA patients received CYC and 24 did ETN; all had biopsy-confirmed AA amyloi‐
dosis. The presence of AA amyloid deposits was confirmed histologically via positive Con‐
go Red staining, potassium permanganate susceptibility, and green birefringence seen by
polarization microscopy after Congo Red staining, as well as immunohistochemical analysis
using anti-AA antibody and anti-immunoglobulin light-chain (AL) antibody to differentiate
AL amyloidosis.
Patients with RA had been treated with non-steroidal anti-inflammatory drugs (NSAIDs),
prednisolone, DMARDs, and immunosuppressive agents but were often refractory to these
agents. Although CYC had been unallowable medico-legally in Japanese governmental
health insurance system and we were able to use CYC for RA treatment from August 2010
in Japan, we finally used CYC and investigated its efficacy for enrolled patients until De‐
cember 2004.
Age, sex, and duration of RA and AA amyloidosis were recorded, as were changes in labo‐
ratory indices and clinical evaluations of disease activity included CRP, SAA, ESR, rheuma‐
toid factor (RF), serum Alb, Crea, 24-hour proteinuria, and eGFR. Use of DMARDs,
immunosuppressants, or PSL from the time of RA onset to the index time was noted. We
chose CRP as an indicator of rheumatoid inflammation and Alb as an indicator of severity of
AA amyloidosis [76]. Because renal dysfunction is the most common symptom in AA amy‐
loidosis secondary to RA, we selected Crea and eGFR to assess treatment effectiveness. We
calculated eGFRs via the nomogram for modification of diet reported in a Japanese renal
disease study (index 0.741) using Crea measured by using an enzymatic method [77]. We al‐
so obtained information on drugs including DMARDs, NSAIDs, angiotensin-converting en‐
zyme inhibitors, and angiotensin II receptor blockers. We recorded clinical symptoms and
arthritis activity for each time point. We carefully checked adverse effects of immunosup‐
pressants, e.g. infection risks, myelosuppression, haemorrhagic cystitis, and carcinogenesis.
We monitored biomarker levels and compared initial (before treatment) and last (after treat‐
ment) values. We used statistical analysis to assess effects of the SAA1.3 allele on therapies.
We determined the onset of RA by reviewing of charts after AA amyloidosis diagnosis had
been confirmed. Clinical symptoms at presentation were the main reason for physicians to
obtain tissue biopsies to demonstrate AA amyloid deposits. We estimated survival curves
via the Kaplan-Maier technique; we analyzed statistical differences between two curves by
the log-rank test. We used Cox proportional hazards models to assess effects of treatments
on eGFR and 24-hour proteinuria, with risk of death as the endpoint. We used two-way re‐
peated-measures analysis of ANOVA to simultaneously estimate effects of SAA1.3 or treat‐
ments on individual changes in biomarkers. In the model, individual change was defined as
within-subjects factors; categorical groups, i.e. polymorphisms of the SAA1.3 allele and
treatments, were defined as between-subjects factors. To determine the factor affecting indi‐
vidual change, a combined factor (within and between) was defined as interaction. We eval‐
uated significant effects of these factors via ANOVA. We determined significant interaction
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of effects of groups (SAA1.3 or treatments) on changes in individual markers. Findings were
statistically significant at P<0.05. We used SPSS Statistics 17.0, Base and Advanced (SPSS Inc,
Chicago, IL, USA) for statistical analyses.
5.2. Results
Table 7 provides patients’ clinical characteristics and laboratory findings. Despite treatments
being administered during different periods, clinical and laboratory findings of both groups
were quite similar at the start of each treatment, except for the SAA1.3 genotype and dura‐
tion AA amyloidosis since diagnosis (P=0.015 and P<0.001, respectively). With regard to bio‐
markers indicating renal dysfunction, ETN had worse kidney damage than did CYC.
During the study, patients died in each treatment group at the almost same rate. In the CYC
group, congestive heart failure and infectious pneumonia occurred frequently. Patients giv‐
en ETN had a lower rate of congestive heart failure as cause of death, suggesting of the pos‐
sibility of an inhibitory effect on progressive heart failure.
Years since RA onset and years since diagnosis of AA amyloidosis were significantly differ‐
ent for SAA1.3 homozygosity vs other genotypes (15.6±7.8 vs 21.4±9.9, P=0.046, and 7.44±4.9
vs 9.7±4.5, P=0.016, respectively). Comparison of CRP, Alb, eGFR, and Crea for both groups
at initial and final observations, disregarding SAA1.3 allele polymorphisms, showed that
ETN reduced serum CRP levels and increased serum Alb levels more than did CYC (ETN vs
CYC: CRP: from 4.7±0.8 to 0.5±0.3 mg/dl vs from 4.0±1.6 to 2.8±1.2 mg/dl, P<0.01; Alb: from
2.6±0.4 to 3.5±0.4 g/dl vs from 2.8±0.3 to 2.8±0.5 g/dl, P<0.01, respectively). Thus, ETN signifi‐
cantly improved serum CRP and Alb levels and was clearly more effective than CYC. CRP
and Alb interactions with polymorphism (homozygous for SAA1.3 or other polymorphisms)
showed no significance (P=0.777 and P=0.715, respectively), but CRP and Alb interactions
with treatment (ETN or CYC) demonstrated significant results (both P<0.01). Within-subject
analysis showed that treatments improved eGFR: ETN: from 21.8±18.9 to 24.9±18.7 ml/min/
1.73m2 vs CYC: from 29.3±12.7 to 18.6±9.3 ml/min/1.73m2, P=0.035, with ETN’s effect on
eGFR being significant (P=0.032). ETN increased eGFR, thus improving the decreased renal
function caused by AA amyloidosis, more than did CYC (Fig. 9A), but this effect was not
related to SAA1.3 allele polymorphisms (Fig. 9B). Neither treatment affected Crea levels.
SAA1.3 allele did not affect treatment in both groups of patients, as evidenced by interac‐
tions of SAA1.3 allele with CRP, Alb, eGFR, and Crea (P=0.777, P=0.715, P=0.465, and
P=0.228, respectively).
Because ETN was more effective than CYC, according to CRP, Alb, and eGFR measures,
we calculated the hazard ratio between ETN and CYC as a survival parameter. According
to  Cox  proportional  hazards  survival  analysis,  ETN  significantly  improved  survival
(P=0.025).  Also,  the  Kaplan-Meier  curves  showed  a  significant  difference  between  ETN
and CYC (Fig. 10). The hazard ratio for ETN evidenced significant results for the risk of
death  endpoint  (eGFR:  P=0.024  and 24-hour  proteinuria:  P=0.025,  respectively)  but  CYC
did not (Table 8).
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CYC (n=62)2) ETN (n=24)3) P-value4)
I. Sex, Male/Female, n 12/50 4/20 1.000
SAA1.3 allele, Homozygout/Others, n 22/40 16/8 0.015
Months since RA onset (mean) 176.0 (111.0) 195.3 (88.3) 0.447
Months since diagnosis of AA
amyloidosis (mean) 22.9(41.7) 67.5 (42.5) <0.001
Months of treatment (mean) 38.0 (27.4) 34.0 (23.1) 0.526
Steinbrocker’s classification5)
Stage II,III,IV, n 5/18/39 3/7/14
Class 2/3/4, n 38/18/6 14/7/3
II MTX therapy (yes/no), n 31/31 15/9 0.297
PSL dosage (mg/day, mean) 9.91(5.88) 7.97 (4.96) 0.516
III CRP (mg/dl, mean) 3.99 (1.72) 3.89 (1.97) 0.820
SAA (μg/ml, mean) 294.8 (166.0) 327.0 (223.4) 0.467
eGFR (ml/min/1.73㎡, mean) 29.2 (23.9) 31.2 (20.6) 0.714
Crea(mg/dl, mean) 2.04 (0.95) 2.23 (1.27) 0.465
24-Hour urinary protein (g, mean) 1.53 (0.84) 2.09 (1.27) 0.020
Serum Alb (g/dl, mean) 2.92 (0.32) 3.04 (0.68) 0.128
RF (U/ml, mean) 237.8 (262.1) 200.8 (154.3) 0.519
IV Cause of death, n (%) n=26 (41.9) n=8 (33.3) 0.464
Infectious pneumonia 6 3
Sepsis 2
GI ulcer/bleeding 3
Interstitial pneumonia 4 1
Myocardial infarction 2
Congestive heart failure 7 2
Renal failure 1 1
Malignancy 1
Unknown 1
1) Baseline data were at the initiation of each treatment. All patients, except those who died, were followed from Janu‐
ary 1995 to December 2010. Last observations were made in December 2004 for the CYC group and December 2010
for the ETN group. Vales are represented by mean (S.D.) unless otherwise noted. Causes of death of patients who died
during the study, and these causes were most closely related to their death. 2)CYC was given until December, 2004.
Thirty-six alive [8 males, 28 females; mean (S.D.) age = 65.7 (10.8) years] and 26 dead [3 males, 23 females; mean (S.D.)
age = 71.9 (8.5) years]. CYC was treated according to the level of 24-h Ccr: Ccr≧80 (ml/min): 100 (mg/day), 60≦Ccr＜
80 (ml/min): 75 (mg/day), 40≦Ccr＜ 60 (ml/min): 40 (mg/day), 10≦Ccr＜ 20 (ml/min): 25 (mg/day), Ccr＜ 10 (ml/
min): 20 (mg /day). 3)ETN was until December, 2010. Sixteen alive [3 males, 13 females; mean (S.D.) age = 64.2 (8.5)
years] and 8 dead [1 male, 7 females; mean (S.D.) age = 66.0 (7.8) years]. 4)Student’s-t analysis was performed to com‐
pare CYC and ETN, with P＜ 0.05 indicating a significant result. 5)Stenbrocher’scalassification according to JAMA 1949;
140: 659-62．Quoted from Reference No. 75.
Table 7. Clinical characteristics and laboratory findings of patients1)
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Figure 9. A) Changes in eGFR between initial- and last-visit as an effect of treatment (ETN or CYC). (B) Changes in
eGFR between initial- and last-visit as an effect of SAA1.3 allele genotype (homozygosity or other polymorphisms).
Quoted and modified from Reference No. 75.
Figure 10. Kaplan-Meier survival curves after treatment with ETN (continuous line) and CYC (dotted line; P=0.025, log-
rank test). Quoted and modified from Reference No. 75.
Amyloidosis230
eGFR 24-Hour proteinuria
Hazard ratio
(95% confidence interval) P-value
Hazard ratio
(95% confidence interval) P-value
ETN 0.949(0.907-0.993) 0.024
1.779
(1.074-2.946) 0.025
CYC 0.951(0.894-1.012) 0.110
1.161
(0.542-2.488) 0.701
Hazard ratio for each treatment using the Cox proportional hazards models to assess effect of treatments
on the risk of death as the endpoint, being determined by two variables, eGFR and 24-h proteinuria.
Quoted and modified from Reference No. 75. ETN: etanercept, CYC: cyclophosphamide, eGFR: estimated
glomerular filtration rate.
Table 8. Hazard ratio for each treatment
5.3. Discussion
The goal of AA amyloidosis therapy is control of the underlying disorder. Treatment sup‐
pressing inflammatory activity reduces circulatory levels of SAA, an acute-phase reactant. In
AA amyloidosis secondary to RA, treatment has focused on using cytotoxic drugs such as
CYC and chlorambucil [29, 32] and more recently on TNFα inhibitors and IL-6 receptor anti‐
body [45,56]. Before the advent of biologics, encouraging reports of alkylating agents as ben‐
efiting RA patients with AA amyloidosis were published. The rationale of this treatment
seems to be similar to autologous stem cell transplantation, which generates new self-toler‐
ant lymphocytes after alkylating agent treatment by eliminating self-reactive lymphocytes
[78]. In the light of the reported superiority of CYC compared with MTX for managing RA
patients with AA amyloidosis [9], using alkylating agents may improve AA amyloidosis.
Cytotoxic drugs and cytokine inhibitors affect AA amyloid deposits by suppressing SAA
production. Also, anti-TNFα therapies, by inhibiting expression of receptors of advanced
glycation end-products (RAGE), may reduce interactions between AA amyloid fibrils and
RAGE and thereby prevent AA-mediated cell toxicity [79, 80]. Thus, our findings that ETN
had greater effects on AA amyloidosis secondary to RA than did CYC was not unexpected,
and early therapeutic intervention in RA may avoid the complication of AA amyloidosis by
controlling rheumatoid disease activity [26].
In Japan, use of MTX to treat with RA patients was permitted in 1999, the maximum dose
being 8 mg/week, until February 2011; use of ETN was allowed in 2005. In our study the
time from diagnosis of AA amyloidosis was shorter for the CYC group than the ETN group
(Table 8), but treatment strategies and DMARDs used were the same, except for the use of
biologics. Although MTX is now considered an anchor drug for RA treatment, it was used
infrequently for AA amyloidosis patients because of its renal damage. No significant differ‐
ences between groups in MTX therapy were found (Table 7). The recovery of Alb biosynthe‐
sis, improved acute-phase response, and ameliorated eGFR are all demonstrable endpoints,
and we suggest that Alb reflects the severity of AA amyloidosis. We found that the different
therapies rather than SAA1.3 allele polymorphism influenced changes in CRP and Alb. Al‐
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so, eGFR may reflect diminished renal blood flow, and only ETN improved eGFR, thus indi‐
cating better renal function and greater efficacy of ETN than CYC (Fig. 9A). We found no
evidence linking SAA1.3 allele to treatment efficacy (Fig. 9B).
6. Conclusion
Although significant advances have been made in understanding of the pathology, pathogene‐
sis, and clinical treatment of AA amyloidosis secondary to RA, the disease is still an important
complication that warrants further investigation. The SAA1.3 allele serves not only as a risk
factor for AA amyloidosis but also as a factor related to poor prognosis and shortened survival
in Japanese patients with RA, and understanding both disorders would benefit from investiga‐
tion of the SAA1.3 allele. AA amyloidosis secondary to RA is now clearly influenced by many
variables, and clinical pictures differ among patients. The pathological process in RA patients
with AA amyloidosis seems to be more complicated and subtle than previously realized. Clari‐
fication of the formation and degeneration or turnover of AA amyloid fibrils and elucidation of
the biological contributions of SAA in health and disease are indispensable prerequisites to the
management of AA amyloidosis secondary to RA. By employing with the newly developed
therapies, AA amyloidosis secondary to RA will already become both treatable and curable
disease. Further, genetic predisposition, SAA1.3 allele genotype, would serve one of personal‐
ized medicines to make AA amyloidosis secondary to RA a preventable disease.
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